Article

Partnership takes IOP monitoring system to Latin America

A new partnership between Addition Technology Inc. and Switzerland-based Sensimed AG will have the former company rolling out the latter company?s IOP monitoring system (Sensimed Triggerfish) in Latin America.

Des Plaines, IL-A new partnership between Addition Technology Inc. and Switzerland-based Sensimed AG will have the former company rolling out the latter company’s IOP monitoring system (Sensimed Triggerfish) in Latin America.

The contact lens continuously monitors IOP fluctuations to facilitate the management of related diseases such as glaucoma. By providing a 24-hour profile of IOP, the technology is designed to help ophthalmologists better understand the condition of the patient, provide personalized treatment, and monitor the efficacy of the treatment over time.

Addition Technology will handle the registration process and the commercialization of the product in Latin America, where a high incidence of glaucoma exists. The company already is broadly present across the continent, maintaining close relationships with key opinion leaders and ophthalmologists, according to its management.

“Their presence and experience in Latin America will open a new market for our company and will enable a large population suffering from glaucoma to have access to our technology,” said Jean-Marc Wismer, chief executive officer (CEO) of Sensimed.

William Flynn, president and CEO of Addition Technology, said, “We are very excited about our relationship with Sensimed and the opportunity to bring this valuable technology to glaucoma specialists in Latin America. I believe this system will completely change the way glaucoma [is] managed in the future.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.